<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chatgilialoglu, C</style></author><author><style face="normal" font="default" size="100%">Ferreri, C</style></author><author><style face="normal" font="default" size="100%">Gimisis, T.</style></author><author><style face="normal" font="default" size="100%">Roberti, M</style></author><author><style face="normal" font="default" size="100%">Balzarini, J.</style></author><author><style face="normal" font="default" size="100%">{De Clercq}, A E</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">{Synthesis and biological evaluation of novel 1 '-branched and spironucleoside analogues}</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleosides Nucleotides {&amp;} Nucleic Acids</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2004</style></year></dates><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">23</style></volume><pages><style face="normal" font="default" size="100%">1565–1581</style></pages><isbn><style face="normal" font="default" size="100%">1525-7770</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Novel anomeric spironucleosides and 1'-cyano-2',3'-didehydro-2',3'-dideoxyuridine, a structural analogue of known anti-HIV agent, were prepared by nucleophilic addition of organolithium reagents to 1'-cyano-2'deoxy- and 1'-cyano-2'-deoxy-2'beta-bromouridine derivatives, respectively. The yield and distribution of products depended on the reaction conditions, whichwere studied in detail. Although none of the compounds exhibited antiviral activit, twocompounds displayed cytostatic activity against both murine leukemia and human T-lymphocyte cells.</style></abstract></record></records></xml>